BioSpace News Archive

Genetown

Novartis Spins Off Sandoz to Maximize Growth of Pharmaceuticals, Biosimilars

Novartis unveiled plans to separate its generics and biosimilars arm, Sandoz, into a standalone entity, allowing both to pursue independent and more business-appropriate growth strategies.

August 25, 2022
·
3 min read
·
Tristan Manalac
Drug Development

AstraZeneca Scores Japanese Approvals in NSCLC, gMG and Breast Cancer

AstraZeneca announced a series of wins in Japan with regulatory approvals for Tagrisso, Ultomiris and Lynparza, to treat non-small cell lung cancer, myasthenia gravis and breast cancer, respectively.

August 25, 2022
·
3 min read
·
Vanessa Doctor, MS
Psilocybin Dramatically Reduces Binge Drinking in Alcohol-Dependent People, Study Finds

Researchers at NYU Langone found that 48% of those who received psilocybin stopped drinking altogether, and the treatment reduced heavy drinking by an average of 83%.

August 25, 2022
·
3 min read
·
Alex Keown
Policy

NIH Study Debunks Long-Held Symptomatic Herpes-Alzheimer’s Connection

NIH researchers found that symptomatic herpes viruses were associated with neurological symptoms, but there was no evidence that herpes viruses are linked to Alzheimer’s disease.

August 25, 2022
·
3 min read
·
Mark Terry
Research Roundup: New Target for Crohn’s, Myocarditis and COVID-19 and a Neuroblastoma Breakthrough

This week’s research roundup includes studies involving Crohn’s disease, myocarditis, COVID-19, a potential cure for childhood brain tumors and more.

August 25, 2022
·
4 min read
·
Mark Terry
Pharm Country

NEJM Study: Omicron Blunts Pfizer’s Paxlovid in Younger Adults

According to a recent study, Pfizer’s Paxlovid appeared to be far more effective at reducing deaths and hospitalizations in older adults than younger patients suffering from the Omicron variant of COVID-19.

August 25, 2022
·
3 min read
·
Tristan Manalac
Policy

BioMarin to Resubmit Hemophilia A Gene Therapy to FDA after EU Approval

BioMarin’s Roctavian was granted conditional authorization in the European Union, making it the first gene therapy approved for severe hemophilia A. Now, the company is shooting for U.S. approval.

August 25, 2022
·
2 min read
·
Alex Keown
Drug Development

Erytech Abandons BLA Plans for Leukemia Drug, Citing Competitive Market

Erytech Pharma is abandoning plans to submit a Biologics License Application to the FDA for Graspa in hypersensitive acute lymphoblastic leukemia.

August 25, 2022
·
2 min read
·
Mark Terry
De-risking and Self Advocacy Key to Changing Women’s Healthcare R&D

Despite an anticipated revenue opportunity of $24.48 billion by 2027, a fraction of R&D funding is currently allocated to this space. BioSpace spoke with Organon’s Sandy Milligan about the challenges and progress.

August 25, 2022
·
5 min read
·
Abbey Glasure
Drug Development

Pfizer Heads to FDA with 85% Efficacy in RSV Vaccine for Older Adults

Pfizer’s RSV vaccine has produced promising data with an efficacy of 85.7% in adults over 60 with a more severe form of the disease. Data in hand, Pfizer plans to head to the FDA this Fall.

August 25, 2022
·
2 min read
·
Katherine Davis